News from alligator bioscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

16 May, 2019, 07:45 BST Alligator Bioscience to Present the ATOR-1015 Phase I Study Outline at ASCO

Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announces that the outline of the ongoing Phase I study with the bispecific drug candidate...


16 May, 2019, 00:29 BST Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study...


17 Apr, 2019, 07:43 BST The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bioscience has presented its proposal for...


17 Apr, 2019, 07:29 BST Alligator Bioscience AB (publ) Interim Report January-March 2019

Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong...


10 Apr, 2019, 09:53 BST Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Chief Medical Officer Charlotte Russell, MD, PhD, will give an oral presentation ...


02 Apr, 2019, 12:42 BST Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the...


22 Mar, 2019, 08:42 GMT Alligator Bioscience's Annual Report 2018 Published

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


18 Mar, 2019, 12:50 GMT Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th...


07 Mar, 2019, 11:11 GMT Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the first patient has successfully been dosed in its phase I study of ATOR-1015,...


14 Feb, 2019, 07:58 GMT Alligator Bioscience AB Year-end Report 2018

Significant events October-December The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New preclinical...


12 Feb, 2019, 13:20 GMT Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update

Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year...


29 Jan, 2019, 07:17 GMT Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the publication of the results from a clinical phase I first-in-human study of the CD40...


07 Jan, 2019, 12:37 GMT Alligator Bioscience Launches RUBY™, a Novel Concept in Bispecific Antibody Formats

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the launch of a novel concept in bispecific antibody formats, RUBY™. The RUBY concept gives ...


11 Dec, 2018, 07:21 GMT Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of...


10 Dec, 2018, 15:31 GMT Frontier - A Magazine about Alligator Bioscience and Immuno-oncology

The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development Read the full magazine through the...


09 Nov, 2018, 05:16 GMT Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


07 Nov, 2018, 16:10 GMT Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than USD 3.5 million under its collaboration...


30 Oct, 2018, 13:12 GMT Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144

Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...


26 Oct, 2018, 07:19 BST Alligator Bioscience AB Interim Report January-September 2018

The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator's research and development. Significant events...


05 Oct, 2018, 10:11 BST Alligator Bioscience Receives Government Research Grant

Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...


28 Sep, 2018, 08:06 BST New Preclinical Data Support Good Tolerability Properties for the 4-1BB Antibody ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


19 Jul, 2018, 15:54 BST Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


12 Jul, 2018, 07:49 BST Alligator Bioscience AB Interim Report January-June 2018

Positive data for our preclinical projects Significant events April-June • The ADC-1013 clinical phase I study performed by Janssen is ongoing with...


21 Jun, 2018, 07:16 BST Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


29 May, 2018, 06:39 BST Alligator Bioscience Capital Markets Day Today on May, 29

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...